TADS study raises concerns [3]

British Medical Journal

Volumn 329, Issue 7478, 2004, Pages 1343-1344

  Jureidini, Jon ^a   Tonkin, Anne ^b   Mansfield, Peter R ^b  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT DISEASE; BEHAVIOR THERAPY; CHILD PSYCHIATRY; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; HUMAN; LETTER; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT;

EID: 16344370976     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Lenzer J. Journalists on Prozac. BMJ 2004;329:748. (25 September.)
2. Treatment for Adolescents with Depression Study Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004;292:807-20.
3. Jureidini J, Doecke C, Mansfield P, Haby M, Menkes D, Tonkin A. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004;328:879-83.